R115
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 103
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.510
- MYC_TARGETS_V2+0.400
- G2M_CHECKPOINT+0.370
- DNA_REPAIR+0.300
- MYC_TARGETS_V1+0.270
- HEME_METABOLISM+0.170
- MITOTIC_SPINDLE+0.160
- ADIPOGENESIS+0.140
- UNFOLDED_PROTEIN_RESPONSE+0.140
- FATTY_ACID_METABOLISM+0.130
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.510
- COAGULATION-0.470
- ALLOGRAFT_REJECTION-0.450
- INFLAMMATORY_RESPONSE-0.440
- INTERFERON_GAMMA_RESPONSE-0.440
- HEDGEHOG_SIGNALING-0.390
- IL6_JAK_STAT3_SIGNALING-0.390
- KRAS_SIGNALING_UP-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- APOPTOSIS-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_NKEAAFMW | medulloblastoma | — | 0.907 |
| 2 | TCGA-63-A5MY-01A-11R-A26W-07 | — | cohortSQ2 | 0.903 |
| 3 | 64935b9c-623d-40d4-bd89-f2af006b1f92 | — | — | 0.903 |
| 4 | fea46737-a2b3-49d4-8358-d0737546b6da | — | — | 0.900 |
| 5 | SRR26320088 | — | — | 0.900 |
| 6 | TCGA-HD-A634-01A-11R-A28V-07 | — | — | 0.898 |
| 7 | ERR2208894 | — | — | 0.897 |
| 8 | TCGA-QK-A6VB-01A-12R-A34R-07 | — | — | 0.897 |
| 9 | BS_KVNGNETA | medulloblastoma | — | 0.895 |
| 10 | TCGA-A8-A09C-01A-11R-A00Z-07 | — | B | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.170 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.110 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.040 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |